{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T05:34:24Z","timestamp":1761197664038,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:00:00Z","timestamp":1559088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010129","name":"Maud Kuistilan Muistos\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["no"],"award-info":[{"award-number":["no"]}],"id":[{"id":"10.13039\/100010129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["667403"],"award-info":[{"award-number":["667403"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40644-019-0215-7","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T13:02:58Z","timestamp":1559134978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Behavior of FDG-avid supradiaphragmatic lymph nodes in PET\/CT throughout primary therapy in advanced serous epithelial ovarian cancer: a prospective study"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3666-2036","authenticated-orcid":false,"given":"Maren","family":"Laasik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jukka","family":"Kemppainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Auranen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakari","family":"Hietanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seija","family":"Gr\u00e9nman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Sepp\u00e4nen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Hynninen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,29]]},"reference":[{"key":"215_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3322\/caac.21235","volume":"64","author":"CE DeSantis","year":"2014","unstructured":"DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252\u201371.","journal-title":"CA Cancer J Clin"},{"key":"215_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","volume":"130","author":"SJ Chang","year":"2013","unstructured":"Chang SJ, Hodeib M, Chang J, et al. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol [Internet] Elsevier Inc. 2013;130:493\u20138. Available from. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.040\n                    \n                  .","journal-title":"Gynecol Oncol [Internet] Elsevier Inc"},{"key":"215_CR3","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"R Bristow","year":"2002","unstructured":"Bristow R, Tomacruz R, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the paltinum era: a meta-analysis. J Clin Oncol. 2002;20:1248\u201359.","journal-title":"J Clin Oncol"},{"key":"215_CR4","doi-asserted-by":"crossref","unstructured":"Hynninen J, Auranen A, Carp\u00e9n O, et al. FDG PET\/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread. Gynecol Oncol. 2012.","DOI":"10.1016\/j.ygyno.2012.04.023"},{"key":"215_CR5","doi-asserted-by":"crossref","unstructured":"Fruscio R, Sina F, Dolci C, et al. Preoperative 18F-FDG PET\/CT in the management of advanced epithelial ovarian cancer. Gynecol Oncol. 2013.","DOI":"10.1016\/j.ygyno.2013.09.024"},{"key":"215_CR6","doi-asserted-by":"crossref","unstructured":"Nam EJ, Yun MJ, Oh YT, et al. Diagnosis and staging of primary ovarian cancer: correlation between PET\/CT, Doppler US, and CT or MRI. Gynecol Oncol. 2010.","DOI":"10.1016\/j.ygyno.2009.10.059"},{"key":"215_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","volume":"124","author":"J Prat","year":"2014","unstructured":"Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet United States. 2014;124:1\u20135.","journal-title":"Int J Gynaecol Obstet United States"},{"key":"215_CR8","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s00259-011-1984-9","volume":"39","author":"AS Bats","year":"2012","unstructured":"Bats AS, Hugonnet F, Huchon C, et al. Prognostic significance of mediastinal 18F-FDG uptake in PET\/CT in advanced ovarian cancer. Eur J Nucl Med Mol Imaging. 2012;39:474\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"215_CR9","doi-asserted-by":"crossref","unstructured":"Raban O, Peled Y, Krissi H, et al. The significance of paracardiac lymph-node enlargement in patients with newly diagnosed stage IIIC ovarian cancer. Gynecol Oncol. 2015.","DOI":"10.1016\/j.ygyno.2015.05.007"},{"key":"215_CR10","doi-asserted-by":"crossref","unstructured":"Lee IO, Lee J-Y, Kim HJ, et al. Prognostic significance of supradiaphragmatic lymph node metastasis detected by 18F-FDG PET\/CT in advanced epithelial ovarian cancer. BMC Cancer [Internet] BioMed Central; 2018 [cited 2019];18:1165. Available from: \n                    https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5067-1","DOI":"10.1186\/s12885-018-5067-1"},{"key":"215_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer England. 2009;45:228\u201347.","journal-title":"Eur J Cancer England"},{"issue":"2","key":"215_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"Gordon John Sampson Rustin","year":"2011","unstructured":"Rustin GJS, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian Cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological Cancer intergroup (GCIG). Int J Gynecol Cancer [Internet]. 2011;21:419\u201323 Available from: \n                    https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21270624\n                    \n                  .","journal-title":"International Journal of Gynecologic Cancer"},{"issue":"Suppl_1","key":"215_CR13","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"R. L. Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med [Internet]. Society of Nuclear Medicine; 2009 [cited 2018];50 Suppl 1:122S\u201350S. Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19403881","journal-title":"Journal of Nuclear Medicine"},{"issue":"1","key":"215_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s13139-011-0115-7","volume":"46","author":"Hyung-Jun Im","year":"2011","unstructured":"Im HJ, Kim Y il, Paeng JC, et al. Retrocrural lymph node metastasis disclosed by 18F-FDG PET\/CT: a predictor of supra-diaphragmatic spread in ovarian Cancer. Nucl Med Mol Imaging (2010) 2012;46:41\u201347.","journal-title":"Nuclear Medicine and Molecular Imaging"},{"key":"215_CR15","doi-asserted-by":"crossref","unstructured":"Signorelli M, Guerra L, Pirovano C, et al. Detection of nodal metastases by 18F-FDG PET\/CT in apparent early stage ovarian cancer: a prospective study. Gynecol Oncol. 2013.","DOI":"10.1016\/j.ygyno.2013.08.022"},{"key":"215_CR16","doi-asserted-by":"crossref","unstructured":"Jamieson A, Sykes P, Eva L, et al. Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence. Gynecol Oncol [Internet]. Elsevier Inc.; 2017; Available from: \n                    http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581730879X","DOI":"10.1016\/j.ygyno.2017.05.023"},{"key":"215_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ygyno.2013.07.093","volume":"131","author":"T Perri","year":"2013","unstructured":"Perri T, Ben-Baruch G, Kalfon S, et al. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction. Gynecol Oncol [Internet]. Elsevier Inc. 2013;131:27\u201331. Available from. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2013.07.093\n                    \n                  .","journal-title":"Gynecol Oncol [Internet]. Elsevier Inc."},{"key":"215_CR18","unstructured":"Hong MKH, Macintyre G, Wedge DC, et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun [internet]. Nat Publ Group. 2015;6:6605 Available from: \n                    https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4396364\/"},{"key":"215_CR19","doi-asserted-by":"crossref","unstructured":"Prader S, Harter P, Grimm C, et al. Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer. Gynecol Oncol. 2016.","DOI":"10.1016\/j.ygyno.2016.03.012"},{"issue":"2","key":"215_CR20","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ygyno.2017.09.001","volume":"147","author":"Renee A. Cowan","year":"2017","unstructured":"Cowan RA, Tseng J, Murthy V, et al. Gynecologic oncology feasibility , safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer. Gynecol Oncol [Internet]. Elsevier Inc. 2017:1\u20135. Available from. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2017.09.001","journal-title":"Gynecologic Oncology"},{"key":"215_CR21","first-page":"1268","volume-title":"Feasibility of Transabdominal Cardiophrenic Lymphnode Dissection in Advanced Ovarian Cancer Initial Experience at a Tertiary Center","author":"A Garbi","year":"2017","unstructured":"Garbi A, Zanagnolo V, Colombo N, et al. Feasibility of Transabdominal Cardiophrenic Lymphnode Dissection in Advanced Ovarian Cancer Initial Experience at a Tertiary Center, vol. 27; 2017. p. 1268\u201373."},{"key":"215_CR22","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1245\/s10434-017-6051-8","volume":"24","author":"S Nasser","year":"2017","unstructured":"Nasser S, Kyrgiou M, Krell J, et al. A review of thoracic and mediastinal Cytoreductive techniques in advanced ovarian Cancer: extending the boundaries. Ann Surg Oncol United States. 2017;24:3700\u20135.","journal-title":"Ann Surg Oncol United States"},{"key":"215_CR23","unstructured":"Mert I, Kumar A, Sheedy SP, et al. Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: Implications for survival. Gynecol Oncol [Internet]. Elsevier Inc. 2017; Available from: \n                    http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817314464\n                    \n                  ."},{"key":"215_CR24","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00330-010-1886-4","volume":"20","author":"R Forstner","year":"2010","unstructured":"Forstner R, Kinkel K, Spencer JA. ESUR guidelines : ovarian cancer staging and follow-up. Eur J Radiol. 2010;20:2773\u201380.","journal-title":"Eur J Radiol"},{"issue":"4","key":"215_CR25","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1245\/s10434-015-5015-0","volume":"23","author":"Tae-Hyung Kim","year":"2015","unstructured":"Kim T-H, Lim MC, Kim SI, et al. Preoperative prediction of Cardiophrenic lymph node metastasis in advanced ovarian Cancer using computed tomography. Ann Surg Oncol [Internet]. 2016;23:1302\u20131308. Available from: \n                    https:\/\/doi.org\/10.1245\/s10434-015-5015-0","journal-title":"Annals of Surgical Oncology"},{"key":"215_CR26","first-page":"1733","volume-title":"Potential Role of Lymphadenectomy in Advanced Ovarian Cancer : A Combined Exploratory Analysis of Three Prospectively Randomized Phase III Multicenter Trials","author":"A Bois","year":"2010","unstructured":"Bois A, Reuss A, Harter P, et al. Potential Role of Lymphadenectomy in Advanced Ovarian Cancer : A Combined Exploratory Analysis of Three Prospectively Randomized Phase III Multicenter Trials, vol. 28; 2010. p. 1733\u20139."},{"issue":"9","key":"215_CR27","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1808424","volume":"380","author":"Philipp Harter","year":"2019","unstructured":"Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med [Internet]. 2019 [cited 2019. 380:822\u201332 Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30811909\n                    \n                  .","journal-title":"New England Journal of Medicine"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-019-0215-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40644-019-0215-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-019-0215-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T23:21:48Z","timestamp":1590621708000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-019-0215-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,29]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["215"],"URL":"https:\/\/doi.org\/10.1186\/s40644-019-0215-7","relation":{},"ISSN":["1470-7330"],"issn-type":[{"type":"electronic","value":"1470-7330"}],"subject":[],"published":{"date-parts":[[2019,5,29]]},"assertion":[{"value":"15 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Ethics committee of the University of Turku, Finland and the signed informed content was all of the participants was collected.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the co-authors have seen the final version of the manuscript and agree on its submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"27"}}